

25 Feb 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 23 February 2024, including: Bayer takes strategic steps to cut debt; AbbVie confirms internal appointment as CEO; another RIPK1 setback for Denali/Sanofi; new biotech reality in China; and ex-Daiichi Sankyo CEO shares insights into tough decisions.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Bayer Cuts Dividend To The Bone To Cut Debt](#)" - Scrip, 21 Feb, 2024.)

(Also see "[AbbVie Stays On Script With Michael As Next CEO](#)" - Scrip, 20 Feb, 2024.)

(Also see "[Sanofi, Denali Drug Fails In ALS, Adding To RIPK1 Program Setbacks](#)" - Scrip, 16 Feb, 2024.)

(Also see "[Hidden Dragon? Investors Return To New China Biotech Reality](#)" - Scrip, 20 Feb, 2024.)

(Also see "[From Ranbaxy Crisis To Enhertu Success: How A New CEO Reshaped Daiichi Sankyo](#)" -

Scrip, 16 Feb, 2024.)

[Click here to explore this interactive content online](#) ✎